Anton Franken, MD, PhD: Monitoring Patients Who Switch to Biosimilars

Anton Franken, MD, PhD, endocrinologist, discusses how closely patients who switch to biosimilars must be monitored.
 
March 28, 2019



Transcript:
It depends on the kind of drug. If you look at insulin, it’s a very safe drug. It’s a small drug. It's a very safe drug, but you must follow patients who react. If you look at [tumor necrosis factor, TNF] blockers, infliximab, they have a chance for immunogenicity, so you have to follow them for a long time, but the discussion in the last session was [that] if a biosimilar is approved by [the European Medicines Agency, EMA], it is equally effective and safe, because all the aspects were researched during the registration process. So I think you must follow a patients, but not too intensively.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.